Stock Events

Stock Events

Insulet 

$147.48
152
-$3.10-2.06% Friday 20:00
+$2.23+1.51%Friday 23:40After hours

Statistics

Day High
147.48
Day Low
147.34
52W High
354.88
52W Low
126.4
Volume
27,975
Avg. Volume
-
Mkt Cap
10.23B
P/E Ratio
37.77
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
0.79
1.08
1.37
1.66
Expected EPS
1.59186
Actual EPS
N/A

Financials

9.12%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.71BRevenue
247.1MNet Income

Analyst Ratings

182.47Average Price Target
The highest estimate is 277.00.
From 21 ratings within the last 6 months. This is not an investment recommendation.
Buy
52%
Hold
43%
Sell
5%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PODD. It's not an investment recommendation.
NVIDIA
41
NVDA
Microsoft
40
MSFT
Amazon
39
AMZN
Apple
34
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Tandem Diabetes Care
TNDM
Mkt Cap1.49B
Tandem Diabetes Care, Inc. competes directly with Insulet by offering insulin pump therapy for diabetes management, which is a direct alternative to Insulet's Omnipod system.
Medtronic
MDT
Mkt Cap116.77B
Medtronic plc is a major competitor in the insulin pump market, offering a range of products that compete with Insulet's offerings for diabetes management.
Dexcom
DXCM
Mkt Cap34.27B
DexCom, Inc. provides continuous glucose monitoring (CGM) systems that are often used in conjunction with insulin pumps like those offered by Insulet, making them a competitor in the broader diabetes management space.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories offers the FreeStyle Libre, a CGM system that competes with the integrated diabetes management solutions provided by Insulet.
Insulet
PODD
Mkt Cap10.07B
Insulet Corporation is listed as its own competitor due to an error. Please disregard this entry.
Senseonics
SENS
Mkt Cap493.31M
Senseonics Holdings, Inc. offers the Eversense CGM system, which competes in the diabetes management market by providing an alternative to the CGM solutions that can be used with Insulet's products.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk A/S is a leading provider of insulin and other diabetes care products that, while not a direct competitor in the insulin pump market, competes in the broader diabetes management space.
Sanofi
SNY
Mkt Cap107.39B
Sanofi provides a range of diabetes care solutions, including insulin therapies that compete with the insulin management solutions offered by Insulet.
Mannkind
MNKD
Mkt Cap1.27B
MannKind Corporation offers Afrezza, an inhaled insulin, providing a non-injectable alternative to insulin delivery that competes with traditional pump therapies like those offered by Insulet.

About

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Show more...
CEO
Ashley McEvoy
Employees
5400
Country
United States
ISIN
US45784P1012
WKN
000A0MQX8

Listings

MI
IT
1PODD.MI
LSE
GB
0ADR.LSE
XETRA
DE
GOV.XETRA
STU
DE
GOV.STU

0 Comments

Share your thoughts

FAQ

What is Insulet stock price today?▼
The current price of PODD is $147.48 USD — it has decreased by -2.06% in the past 24 hours. Watch Insulet stock price performance more closely on the chart.
What is Insulet stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Insulet stocks are traded under the ticker PODD.
Is Insulet stock price growing?▼
PODD stock has risen by +1.62% compared to the previous week, the month change is a +10.67% rise, over the last year Insulet has showed a -57.67% decrease.
What is Insulet market cap?▼
Today Insulet has the market capitalization of 10.23B
When is the next Insulet earnings date?▼
Insulet is going to release the next earnings report on October 29, 2026.
What were Insulet earnings last quarter?▼
PODD earnings for the last quarter are 1.66 USD per share, whereas the estimation was 1.47 USD resulting in a +13.11% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Insulet revenue for the last year?▼
Insulet revenue for the last year amounts to 2.71B USD.
What is Insulet net income for the last year?▼
PODD net income for the last year is 247.1M USD.
How many employees does Insulet have?▼
As of September 05, 2026, the company has 5,400 employees.
In which sector is Insulet located?▼
Insulet operates in the Health & Wellness sector.
When did Insulet complete a stock split?▼
Insulet has not had any recent stock splits.
Where is Insulet headquartered?▼
Insulet is headquartered in ACTON, United States.